Targeting the lung using siRNA and antisense based oligonucleotides

Sterghios Moschos; Karen Spinks; Andrew Evan Williams; Mark Lindsay

doi:10.2174/138161208786898851

Targeting the lung using siRNA and antisense based oligonucleotides

Sterghios Moschos, Karen Spinks, Andrew Evan Williams, Mark Lindsay

Research output: Contribution to journal › Article › peer-review

19 Citations (Scopus)

Abstract

The accessibility to topical administration through inhalation, combined with its large surface area, has led to speculation that the lung might offer an ideal target for the application of oligonucleotide based therapeutics. In this review, we shall critically examine the challenges facing antisense and siRNA based approaches for target validation in vivo and as potential therapeutics. In particular, we shall discuss the antisense and siRNA based approaches in relation to factors such as delivery, distribution, stability, off-target effects, unwanted immune responses and the selection of the optimum mRNA targets.

Original language	English
Pages (from-to)	3620-3627
Journal	Current Pharmaceutical Design
Volume	14
Issue number	34
DOIs	https://doi.org/10.2174/138161208786898851
Publication status	Published - 2008

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.2174/138161208786898851

Cite this

@article{2953a494b27e47a9a2a4bed3c9377695,

title = "Targeting the lung using siRNA and antisense based oligonucleotides",

abstract = "The accessibility to topical administration through inhalation, combined with its large surface area, has led to speculation that the lung might offer an ideal target for the application of oligonucleotide based therapeutics. In this review, we shall critically examine the challenges facing antisense and siRNA based approaches for target validation in vivo and as potential therapeutics. In particular, we shall discuss the antisense and siRNA based approaches in relation to factors such as delivery, distribution, stability, off-target effects, unwanted immune responses and the selection of the optimum mRNA targets.",

author = "Sterghios Moschos and Karen Spinks and Williams, \{Andrew Evan\} and Mark Lindsay",

year = "2008",

doi = "10.2174/138161208786898851",

language = "English",

volume = "14",

pages = "3620--3627",

journal = "Current Pharmaceutical Design",

issn = "1381-6128",

publisher = "Bentham Science Publishers",

number = "34",

}

TY - JOUR

T1 - Targeting the lung using siRNA and antisense based oligonucleotides

AU - Moschos, Sterghios

AU - Spinks, Karen

AU - Williams, Andrew Evan

AU - Lindsay, Mark

PY - 2008

Y1 - 2008

N2 - The accessibility to topical administration through inhalation, combined with its large surface area, has led to speculation that the lung might offer an ideal target for the application of oligonucleotide based therapeutics. In this review, we shall critically examine the challenges facing antisense and siRNA based approaches for target validation in vivo and as potential therapeutics. In particular, we shall discuss the antisense and siRNA based approaches in relation to factors such as delivery, distribution, stability, off-target effects, unwanted immune responses and the selection of the optimum mRNA targets.

AB - The accessibility to topical administration through inhalation, combined with its large surface area, has led to speculation that the lung might offer an ideal target for the application of oligonucleotide based therapeutics. In this review, we shall critically examine the challenges facing antisense and siRNA based approaches for target validation in vivo and as potential therapeutics. In particular, we shall discuss the antisense and siRNA based approaches in relation to factors such as delivery, distribution, stability, off-target effects, unwanted immune responses and the selection of the optimum mRNA targets.

UR - https://www.scopus.com/pages/publications/59849128456

U2 - 10.2174/138161208786898851

DO - 10.2174/138161208786898851

M3 - Article

SN - 1381-6128

VL - 14

SP - 3620

EP - 3627

JO - Current Pharmaceutical Design

JF - Current Pharmaceutical Design

IS - 34

ER -

Targeting the lung using siRNA and antisense based oligonucleotides

Abstract

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this